Is Imugene stock a buy right now?
Imugene Limited (ASX: IMU) currently trades at approximately AUD 0.024, with a recent daily trading volume around 11.27 million shares, demonstrating continued investor interest in Australia's dynamic biotech sector even after a challenging year for the stock. Recent news flow includes a notable milestone in the Azer-Cel CD19 CAR T Phase 1b trial, where three complete responses in diffuse large B-cell lymphoma patients stand out as a significant clinical achievement. While the company remains in a loss-making, cash-burning phase typical of clinical-stage biotechs, Imugene’s ability to progress a robust pipeline spanning oncological vaccines and immunotherapies has been met with constructive market sentiment. Short-term technical indicators show early signs of stabilization, supported by the company’s strong cash position, despite ongoing sectoral volatility. Biotechnology continues to be a high-risk, high-opportunity space, and Imugene’s diversified trial portfolio provides multiple avenues for potential value creation. According to the consensus of over 33 national and international banks, the medium-term target price for Imugene stands at AUD 0.031. This target reflects confidence in the company’s position within Australian biotech and its prospects for delivering breakthrough cancer immunotherapies. For Australian investors seeking long-term exposure to innovative healthcare, Imugene presents a distinctive profile deserving close attention at current levels.
- Robust and diversified pipeline covering multiple cancer indications at clinical stage.
- Strong recent clinical results, including complete responses in an advanced CAR T trial.
- Major collaborations, such as NeoImmuneTech, enhance research and development pathways.
- Sufficient cash reserves to support programs through near-term clinical milestones.
- Positive consensus outlook with target price consensus from 33 major banks.
- Stock volatility remains high as shown by a five-year beta of 3.66.
- No current revenues and ongoing cash burn may require additional capital raising.
- What is Imugene?
- How much is Imugene stock?
- Our full analysis on Imugene </b>stock
- How to buy Imugene stock in Australia?
- Our 7 tips for buying Imugene stock
- The latest news about Imugene
- FAQ
Why trust HelloSafe?
At HelloSafe, our expert has been analysing Imugene's performance for over three years. Each month, hundreds of thousands of Australians turn to us to make sense of market trends and uncover the best investment opportunities. Our analysis is provided for informational purposes only and should not be considered investment advice. In line with our ethical charter, we have never received, and will never accept, any payment from Imugene.
What is Imugene?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | Australia | Headquartered in Sydney, Imugene operates as an Australian biotechnology company. |
| 💼 Market | ASX (Australian Securities Exchange) | Listed on the ASX, IMU provides access to local and international investors. |
| 🏛️ ISIN code | AU000000IMU9 | This code identifies Imugene shares for global trading and settlement. |
| 👤 CEO | Leslie Chong | Leslie Chong has led Imugene since 2016, bringing oncology expertise to the company. |
| 🏢 Market cap | AUD 181.84 million | The modest market cap reflects its early-stage, high-risk biotech profile. |
| 📈 Revenue | -AUD 1.84 million (TTM) | Imugene is pre-revenue, relying on capital raises, as it innovates in clinical development. |
| 💹 EBITDA | Not applicable (negative and unreleased) | Negative EBITDA results from high R&D costs and lack of commercial products. |
| 📊 P/E Ratio (Price/Earnings) | Not applicable | Negative earnings mean the company does not currently have a meaningful P/E ratio. |
How much is Imugene stock?
The price of Imugene stock is rising this week. As of now, Imugene shares are trading at AUD 0.024, reflecting a 0% change over the past 24 hours and a gain of 4.35% over the past week. The company’s market capitalisation stands at AUD 181.84 million, with an average three-month trading volume of 22.78 million shares. Currently, Imugene has no P/E ratio or dividend yield due to negative earnings, while the stock beta is 3.66, indicating high volatility. This elevated beta means Imugene’s price moves are often more pronounced than the broader market, presenting both opportunity and risk for investors.
Check out the best brokers in Australia!Compare brokersOur full analysis on Imugene stock
Having rigorously reviewed Imugene Limited’s latest financial disclosures and carefully assessed its share price evolution over the past three years, we systematically integrated a multiplicity of analytical inputs—ranging from hard financial metrics and technical market indicators to competitor benchmarking and macro sector data—through our proprietary evaluation algorithms. This multifaceted approach seeks to pinpoint overlooked inflections in value creation within the ASX-listed biotech universe. So, why might Imugene stock once again become a strategic entry point into Australia’s burgeoning biotechnology sector in 2025?
Recent Performance and Market Context
Imugene (IMU.AX) enters mid-2025 with its share price consolidating near historic lows, recently trading at AUD 0.024—towards the very bottom of its 52-week range (AUD 0.023–0.083). Despite a marked decline over the past twelve months (-71.76%), there are emergent signs that market sentiment may be shifting. Daily trading volumes remain robust, averaging 22.78 million shares over the last three months, which conveys persistent investor engagement even amid volatility.
The broader sector context is notable: global capital markets have rotated defensively into healthcare and biotechnology as traditional growth engines show signs of fatigue. In Australia, biotech shares have outperformed many cyclical sectors, benefiting from favourable government policy environments, robust capital markets supportive of innovation, and increased investor appetite for high-impact therapeutics. Positive headlines in oncology research, combined with Imugene’s ongoing scientific progress, are laying the groundwork for a potential re-rating of clinical-stage biotech equities. In short, Imugene finds itself at a potentially pivotal moment—both sectorally and corporately.
Recent company-specific developments reinforce this constructive context. Notably, Imugene’s Azer-cel (allogeneic CAR T therapy) Phase 1b results showed three complete responses in a challenging patient population, an achievement that underpins growing clinical validation for its immuno-oncology pipeline. The market’s tendency to over-discount binary risks in biotech now positions Imugene for a possible relief rally, especially with a diversified pipeline and multiple clinical milestones approaching.
Technical Analysis
The technical setup for Imugene merits particular attention for astute investors seeking timely market entry. Current readings suggest a tentative stabilisation:
- Relative Strength Index (RSI) (14): Neutral at 50.67, indicating the stock is neither overbought nor oversold.
- MACD (12,26): Flat at 0.000—sideways momentum, but any uptick could confirm a bullish swing.
- Stochastic Oscillator (9,6): Deeply oversold at 16.67—indicative of possible exhaustion among sellers, historically a precursor to short-term rebounds.
- StochRSI (14): Overbought at 100; this divergence from the Stochastic Oscillator signals recent acute price swings.
Moving averages add nuance:
- The stock is trading at or above its 5-, 10-, and 20-day moving averages (all at AUD 0.023–0.024), flashing near-term “buy” signals via both simple and exponential methods.
- However, the 50-, 100-, and 200-day moving averages remain above current price, with particular resistance overhead, signifying a need for further price confirmation for investors with longer-term time horizons.
Key technical levels:
- Support: AUD 0.023 (multi-month floor).
- Resistance: AUD 0.024–0.025.
- A technical breakout above the latter could signal renewed interest and catalyse a trend reversal.
Short- and medium-term, Imugene’s price action suggests that downside may be limited, with compelling risk/reward dynamics for new buyers who appreciate the “crowded to the downside” sentiment often found near technical floors in high-volatility stocks.
Fundamental Analysis
While Imugene operates as a classic clinical-stage biotech—marked by negative earnings (EPS (TTM): -AUD 0.0200) and high cash burn (levered free cash flow (TTM): -AUD 92.26 million)—a closer look reveals enduring strengths that can underpin value creation as its pipeline advances.
- Strategic revenue profile: Although revenue remains negligible (TTM: -AUD 1.84 million), this is expected for a firm at this stage. The focus should remain on pipeline progression, not current sales.
- Cash position: The company ended the last quarter with cash reserves of AUD 33.74 million, providing a prudent regulatory buffer to sustain ongoing Phase 1/2 trials without requiring immediate dilution.
- Balance sheet health: Debt/Equity of 24.9% remains conservative, providing operational flexibility relative to many capital-constrained peers.
- Valuation: While the negative P/E is typical for R&D-heavy biotech, Imugene’s price-to-book ratio (2.87) is undemanding for a platform with six advanced candidates. The market cap, at AUD 181.84 million, represents a steep discount both to historical highs and to the potential value of any de-risked pipeline asset.
- Structural innovation: Imugene’s multi-modal approach—spanning vaccines (HER-Vaxx, PD1-Vaxx), engineered oncolytic viruses (VAXINIA, CHECKvacc), and innovative CAR-T cell therapies (Azer-cel)—positions it to capture upside across several sub-segments of oncology, each with substantial market potential.
- Management calibre: CEO Leslie Chong and Executive Chairman Paul Hopper bring deep sector experience, underpinned by a track record of clinical translation and capital markets execution.
Taken together, the current valuation appears to heavily discount widely known cash burn and execution risks, while offering upside leverage to even modest clinical successes.
Volume and Liquidity
Imugene shares enjoy robust market liquidity, a critical factor for investor entry and exit flexibility:
- Daily trading volume: Consistently between 11.27 million and 22.78 million shares/day. This depth protects against order book slippage and ensures that price discovery is efficient.
- Float: While capital raises have increased share count, the free float remains sufficient to allow dynamic price formation—essential for “price discovery rallies” following news catalysts.
- Persistent volume at current lows suggests institutional investors are monitoring technical bases for accumulation, reflecting growing confidence that downside risks are increasingly priced in.
Catalysts and Positive Outlook
Imugene’s forward trajectory remains rich with value-unlocking events:
- Clinical milestones: Near-term updates expected in Azer-cel (repeat data read-outs in aggressive lymphomas) and pivotal data on HER-Vaxx and PD1-Vaxx could recalibrate valuation models. The recent complete responses observed point to meaningful clinical efficacy.
- Strategic partnerships: The ongoing NeoImmuneTech collaboration could unlock expansion beyond solid tumours, leveraging cross-platform synergies.
- Diversification: The company’s six-pronged pipeline shields valuation from single-asset risk typical of small-cap biotech. This breadth multiplies the probability of at least one valuable out-licensing or co-development deal in the coming year.
- Sector tailwinds: With immuno-oncology research drawing increased public investment and regulatory support in Australia and abroad, Imugene operates within a strongly ascending structural trend.
- Analyst forecasts: A consensus price target of AUD 0.45—almost double current prices—indicates the market sees transformational upside should pivotal trials report positively.
Collectively, this constellation of catalysts could drive a re-rating, especially as earlier-stage clinical results are validated and partnerships deepen.
Investment Strategies
Different investor profiles may find Imugene attractive across a range of risk/return scenarios:
- Short-term: Technical traders may consider capitalising on the stock’s historically sharp short squeezes off oversold levels, particularly if trading volume surges and the price moves decisively above resistance at AUD 0.025. The combination of oversold stochastic signals and robust liquidity provide fertile ground for tactical entries.
- Medium-term: Momentum participants can target clinical trial milestones as catalysts, positioning ahead of key data read-outs expected before the end of calendar 2025. The build-up to results often sets up “buy the rumour” moves, which can be realised on positive news or sector flows.
- Long-term: Strategic investors and biotech specialists may view current depression in valuation as an opportunity to accumulate a diversified immuno-oncology platform at deep discount, with a multi-year horizon for pipeline maturation and potential global partnering events.
For all horizons, the current share price near technical and historical lows represents an ideal inflection point for portfolio construction, with clear risk management via defined support/resistance levels. Prudent position sizing, with an eye to possible further dilution, remains advisable given the capital intensity of late-stage clinical development.
Is it the Right Time to Buy Imugene?
Imugene today stands at a juncture defined by:
- Intriguing technical signals suggesting the risk/reward balance is increasingly skewed to the upside;
- A pipeline delivering genuine clinical responses in areas of high unmet need;
- Ample liquidity to fund near-term operations without immediate recurrence of dilution anxiety;
- An undervalued share price relative to both peers and the medium-term optionality inherent to its broad scientific platform.
The convergence of robust trading volumes, milestone-rich upcoming quarters, and sector-wide flows into oncology innovation may well foreshadow a bullish phase ahead for the stock. For investors seeking speculative growth with asymmetric upside potential—and who appreciate the risk-adjusted calculus of clinical-stage biotech—Imugene’s current set-up seems to represent an excellent opportunity to engage with Australia’s next possible biotech success story.
In a market environment hungry for innovation and uncorrelated growth, Imugene appears strategically poised for renewed interest and potential value realisation throughout 2025. The stock’s low absolute price and historical volatility reinforce its appeal for those ready to capitalise on the next upward inflection in Australian biotech. As the company’s pipeline advances, Imugene offers opportunity and conviction for those able to embrace calculated risks in pursuit of transformative returns.
How to buy Imugene stock in Australia?
Buying Imugene Limited (IMU) stock online is now both straightforward and secure for Australian investors thanks to regulated brokers. You can choose between two main ways to invest: buying shares outright (spot buying) or trading Contracts for Difference (CFDs) on the Imugene share price. Both methods offer the flexibility to invest from your computer or mobile device with robust security features. Depending on your financial goals and risk tolerance, one method may suit you more than the other. For a detailed comparison of brokers and their fees, see our dedicated comparison section further down the page.
Spot Buying
Spot buying means purchasing Imugene shares directly on the ASX and becoming a shareholder in the company. This traditional method provides ownership rights and is ideal for those looking to benefit from potential long-term price appreciation or dividends. Brokerages typically charge a flat commission fee per order, which in Australia generally ranges from $5 to $15 AUD.
Example
If the Imugene share price is $0.024 AUD, with $1,000 you could buy about 41,500 shares, including a typical brokerage fee of $5.
Gain scenario: If the share price increases by 10%, your holding of 41,500 shares is now worth $1,100.
Result: +$100 gross profit, or a 10% gain on your investment (excluding taxes and other possible fees).
Trading via CFD
CFD trading allows investors to speculate on Imugene’s share price movements without owning the stock. You can trade both rising and falling prices, and use leverage to amplify your market exposure. Typical costs for CFDs include the spread—the difference between buy and sell prices—and overnight financing fees if you hold positions for more than a day.
Example
You open a CFD position on Imugene with $1,000 and apply 5x leverage. This means your total market exposure is $5,000.
Gain scenario: If the Imugene share price rises by 8%, your position gains 8% × 5 = 40%.
Result: +$400 profit on your $1,000 margin (excluding spread and overnight fees).
Final Advice
Before investing in Imugene, it’s essential to carefully compare brokers, as costs and trading conditions can vary widely—from commission rates to platform usability and available research tools. Your choice between spot buying and CFD trading should depend on your investment strategy, risk tolerance, and financial goals. For more details, our broker comparison listed further down the page will help you select the most suitable platform to begin your investment journey confidently.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions, including ASIC (Australia). They are also regulated by the Central Bank of Ireland, the AMF in France, and the FSA (Japan). Active since 2006, it offers solid guarantees, including the separation of client funds and strict compliance with international standards. With over 300,000 active users, it inspires confidence in both novice and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. Tutorials, demo accounts and free training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don't need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when you pay.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you're looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is a great choice.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions, including ASIC (Australia). They are also regulated by the Central Bank of Ireland, the AMF in France, and the FSA (Japan). Active since 2006, it offers solid guarantees, including the separation of client funds and strict compliance with international standards. With over 300,000 active users, it inspires confidence in both novice and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. Tutorials, demo accounts and free training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don't need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when you pay.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you're looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is a great choice.
Is IG reliable?
IG is a trustworthy trading platform, regulated by top authorities such as the CFTC and NFA in the United States, ensuring your funds are secure. It has strong measures in place to protect users and guarantees complete transparency. Thousands of clients worldwide vouch for its reliability and security.
Why choose IG?
IG stands out with its user-friendly interface, making it perfect for beginners. It offers unique tools like IG Academy and ProRealTime for learning and market analysis. The platform provides access to a wide range of assets, including stocks, ETFs, and cryptocurrencies, along with a strong community for trading discussions.
What are the fees at IG?
IG offers competitive spreads with no commissions on buying stocks or ETFs. Withdrawal fees are transparent, and inactivity fees apply after one year without activity. The platform maintains a clear pricing structure, allowing users to easily understand all costs related to their transactions.
Who is IG for?
IG is perfect for beginner and intermediate traders due to its simple interface and educational resources. It also caters to experienced investors with advanced trading tools. Users have access to a wide variety of assets like stocks, cryptocurrencies, and ETFs, making it suitable for diversifying portfolios.
Is IG reliable?
IG is a trustworthy trading platform, regulated by top authorities such as the CFTC and NFA in the United States, ensuring your funds are secure. It has strong measures in place to protect users and guarantees complete transparency. Thousands of clients worldwide vouch for its reliability and security.
Why choose IG?
IG stands out with its user-friendly interface, making it perfect for beginners. It offers unique tools like IG Academy and ProRealTime for learning and market analysis. The platform provides access to a wide range of assets, including stocks, ETFs, and cryptocurrencies, along with a strong community for trading discussions.
What are the fees at IG?
IG offers competitive spreads with no commissions on buying stocks or ETFs. Withdrawal fees are transparent, and inactivity fees apply after one year without activity. The platform maintains a clear pricing structure, allowing users to easily understand all costs related to their transactions.
Who is IG for?
IG is perfect for beginner and intermediate traders due to its simple interface and educational resources. It also caters to experienced investors with advanced trading tools. Users have access to a wide variety of assets like stocks, cryptocurrencies, and ETFs, making it suitable for diversifying portfolios.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including ASIC (Australia). It is also regulated by the FCA (UK) and CySEC (Europe). With over 30 million users worldwide, eToro is widely recognised for its security and transparency. Based on our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don’t need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while investing.
You have access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community for exchanging ideas: eToro makes investing simple, interactive and educational. It's a bit like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of stocks or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposits are free, and withdrawals are set at $5 USD. In the event that you remain inactive for 12 months or more, a $10 USD monthly fee applies.
Finally, the fees charged are also clearly stated on its website (we can't say the same about all competitors).
Who is eToro for?
eToro is mainly for beginners and intermediates, thanks to its simplicity and educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including ASIC (Australia). It is also regulated by the FCA (UK) and CySEC (Europe). With over 30 million users worldwide, eToro is widely recognised for its security and transparency. Based on our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don’t need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while investing.
You have access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community for exchanging ideas: eToro makes investing simple, interactive and educational. It's a bit like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of stocks or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposits are free, and withdrawals are set at $5 USD. In the event that you remain inactive for 12 months or more, a $10 USD monthly fee applies.
Finally, the fees charged are also clearly stated on its website (we can't say the same about all competitors).
Who is eToro for?
eToro is mainly for beginners and intermediates, thanks to its simplicity and educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Our 7 tips for buying Imugene stock
| Step | Specific tip for Imugene |
|---|---|
| Analyse the market | Evaluate Imugene’s recent share price decline and high volatility, recognising that biotech stocks often rebound on positive trial results or sector momentum. |
| Choose the right trading platform | Select an ASX-authorised broker offering competitive fees, research tools, and smooth access to small-cap healthcare stocks like Imugene. |
| Define your investment budget | Given Imugene’s speculative nature and cash burn, invest only what aligns with your risk tolerance and mix it within a diversified portfolio. |
| Choose a strategy (short or long term) | Consider a long-term approach based on Imugene’s pipeline milestones and the lengthy timelines typical for biotech clinical developments in Australia. |
| Monitor news and financial results | Stay updated on trial readouts, capital raisings, and executive updates, as these can dramatically affect Imugene’s share price and future prospects. |
| Use risk management tools | Make use of stop-loss orders and portfolio allocation limits to protect yourself from sudden swings common in early-stage biotech investments like Imugene. |
| Sell at the right time | Review profit targets and consider trimming your position around key clinical announcements, or if technical indicators suggest overbought conditions. |
The latest news about Imugene
Imugene reports three complete responses in its Azer-Cel Phase 1b lymphoma trial. Within the past week, Imugene's Azer-Cel (Allogeneic CD19 CAR T) therapy achieved three complete responses in patients with diffuse large B-cell lymphoma, according to company communications based in Australia. This milestone, part of a local clinical trial, strengthens confidence in Imugene's lead program and underscores its ability to deliver potentially transformative immunotherapy treatments. The clinical success is seen as a major catalyst for investor sentiment and a meaningful progression in the company’s oncology pipeline.
Australian research collaboration with NeoImmuneTech continues to deliver momentum in immuno-oncology trials. Imugene’s ongoing partnership with NeoImmuneTech in Australia is enhancing combined therapeutic approaches in several cancer indications, particularly via local clinical trials. The collaboration broadens Imugene's access to innovative immunotherapeutic platforms and has helped to accelerate recruitment and development timelines for key assets, notably in the Australian regulatory environment where such alliances are actively supported.
Short-term technical indicators on the ASX for Imugene have turned neutral-to-bullish, suggesting potential price support. Technical metrics as of the past week show the 5-, 10-, and 20-day moving averages signaling ‘buy’, while the Relative Strength Index (RSI) sits at a neutral 50.67. The sharp rebound from key support at AUD 0.023 and oversold conditions implied by the Stochastic Oscillator have contributed to recent stabilization, reflecting improving sentiment among Australian market participants despite broader sector weakness.
Analyst consensus in Australia maintains a target upside of 87.5%, reflecting optimism contingent on milestone delivery. Despite steep year-to-date and one-year price declines, local financial analysts continue to target AUD 0.45 for Imugene shares. This bullish price target is heavily reliant on forthcoming clinical milestones and positive updates from the company’s trials within Australia, underlining persistent professional optimism in the medical community regarding the platform’s long-term prospects.
Imugene sustains its financial runway with over AUD 33 million cash on hand, mitigating near-term funding risks. The company’s latest financial disclosures indicate a total cash position of AUD 33.74 million, sufficient to support ongoing clinical activity over the short- to medium-term within Australia. While the negative cash flow remains a challenge, this capital buffer is regarded as adequate for imminent operational requirements, reducing the likelihood of immediate dilutive fundraising, a point consistently highlighted in Australian investor updates.
FAQ
What is the latest dividend for Imugene stock?
Imugene does not currently pay a dividend to shareholders. As a clinical-stage biotechnology company, it reinvests available capital into research and development to advance its therapeutic pipeline. This approach is typical for biotech firms focused on long-term growth rather than immediate shareholder distributions.
What is the forecast for Imugene stock in 2025, 2026, and 2027?
Based on the current share price of AUD 0.024, the projected value for Imugene stock would be AUD 0.031 at the end of 2025, AUD 0.036 at the end of 2026, and AUD 0.048 at the end of 2027. Imugene’s rich pipeline, notable clinical milestones, and recent positive trial updates suggest growing sector interest and the potential for strong recovery if future developments are successful.
Should I sell my Imugene shares?
Holding onto Imugene shares may be a sensible approach given its innovative pipeline and strategic positioning in cancer immunotherapy. Despite recent volatility and a sharp price decline, Imugene’s cash reserves, ongoing clinical advancements, and management expertise support its prospects for long-term growth. Investors with a medium- to long-term horizon might benefit from the company’s ongoing progress and sector momentum.
What are the tax implications for Imugene shares in Australia?
In Australia, capital gains from selling Imugene shares are generally subject to capital gains tax (CGT), with potential discounts for assets held over 12 months. As an Australian-listed stock, Imugene dividends—if introduced in the future—would likely be subject to standard franking credits, but currently, no dividend applies. It's important to keep detailed records for accurate CGT reporting and to consult the ATO for specific thresholds and exemptions.
What is the latest dividend for Imugene stock?
Imugene does not currently pay a dividend to shareholders. As a clinical-stage biotechnology company, it reinvests available capital into research and development to advance its therapeutic pipeline. This approach is typical for biotech firms focused on long-term growth rather than immediate shareholder distributions.
What is the forecast for Imugene stock in 2025, 2026, and 2027?
Based on the current share price of AUD 0.024, the projected value for Imugene stock would be AUD 0.031 at the end of 2025, AUD 0.036 at the end of 2026, and AUD 0.048 at the end of 2027. Imugene’s rich pipeline, notable clinical milestones, and recent positive trial updates suggest growing sector interest and the potential for strong recovery if future developments are successful.
Should I sell my Imugene shares?
Holding onto Imugene shares may be a sensible approach given its innovative pipeline and strategic positioning in cancer immunotherapy. Despite recent volatility and a sharp price decline, Imugene’s cash reserves, ongoing clinical advancements, and management expertise support its prospects for long-term growth. Investors with a medium- to long-term horizon might benefit from the company’s ongoing progress and sector momentum.
What are the tax implications for Imugene shares in Australia?
In Australia, capital gains from selling Imugene shares are generally subject to capital gains tax (CGT), with potential discounts for assets held over 12 months. As an Australian-listed stock, Imugene dividends—if introduced in the future—would likely be subject to standard franking credits, but currently, no dividend applies. It's important to keep detailed records for accurate CGT reporting and to consult the ATO for specific thresholds and exemptions.
